These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 2567965

  • 1. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM, Cereska KS.
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [Abstract] [Full Text] [Related]

  • 2. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ, Marshall JF.
    Behav Brain Res; 1990 May 28; 38(3):233-42. PubMed ID: 1973041
    [Abstract] [Full Text] [Related]

  • 3. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors?
    White FJ, Bednarz LM, Wachtel SR, Hjorth S, Brooderson RJ.
    Pharmacol Biochem Behav; 1988 May 28; 30(1):189-93. PubMed ID: 2902644
    [Abstract] [Full Text] [Related]

  • 4. Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioral responses: a quantitative phenomenological study in rats.
    Longoni R, Spina L, Di Chiara G.
    Life Sci; 1987 Nov 02; 41(18):2135-45. PubMed ID: 2959833
    [Abstract] [Full Text] [Related]

  • 5. D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors.
    Koller WC, Herbster G.
    Clin Neuropharmacol; 1988 Jun 02; 11(3):221-31. PubMed ID: 3261198
    [Abstract] [Full Text] [Related]

  • 6. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG, Walters JR.
    Brain Res; 1987 Mar 10; 405(2):234-46. PubMed ID: 2952219
    [Abstract] [Full Text] [Related]

  • 7. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.
    Zarrindast MR, Poursoltan M.
    Br J Pharmacol; 1989 Apr 10; 96(4):843-8. PubMed ID: 2663110
    [Abstract] [Full Text] [Related]

  • 8. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH, Starr MS.
    Neuroscience; 1987 Dec 10; 23(3):1001-10. PubMed ID: 2963970
    [Abstract] [Full Text] [Related]

  • 9. Differential effects of dopamine D-1 and D-2 receptor agonists on EEG activity and behaviour in the rabbit.
    Ongini E, Caporali MG.
    Neuropharmacology; 1987 Apr 10; 26(4):355-60. PubMed ID: 2953987
    [Abstract] [Full Text] [Related]

  • 10. Behavioral and biochemical expression of D1-receptor supersensitivity following SCH 23390 repeated administrations.
    Gandolfi O, Roncada P, Dall'Olio R, Montanaro N.
    Brain Res; 1988 Jul 12; 455(2):390-3. PubMed ID: 2969768
    [Abstract] [Full Text] [Related]

  • 11. Enhancement by the D1 dopamine agonist SKF 38393 of specific components of stereotypy elicited by the D2 agonists LY 171555 and RU 24213.
    Meller E, Bordi F, Bohmaker K.
    Life Sci; 1988 Jul 12; 42(25):2561-7. PubMed ID: 3260320
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity.
    Johnson KB, Criswell HE, Jensen KF, Simson PE, Mueller RA, Breese GR.
    J Pharmacol Exp Ther; 1992 Aug 12; 262(2):855-65. PubMed ID: 1354257
    [Abstract] [Full Text] [Related]

  • 13. Behavioral differentiation of the stimulus properties of a dopaminergic D1 agonist from a D2 agonist.
    Cory-Slechta DA, Widzowski DV, Newland MC.
    J Pharmacol Exp Ther; 1989 Sep 12; 250(3):800-8. PubMed ID: 2789282
    [Abstract] [Full Text] [Related]

  • 14. Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK&F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide.
    Molloy AG, Waddington JL.
    Eur J Pharmacol; 1985 Feb 05; 108(3):305-8. PubMed ID: 3886407
    [Abstract] [Full Text] [Related]

  • 15. Behavioural interactions involving D1 and D2 dopamine receptors in non-habituated mice.
    Starr BS, Starr MS.
    Neuropharmacology; 1987 Jun 05; 26(6):613-9. PubMed ID: 2955244
    [Abstract] [Full Text] [Related]

  • 16. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse.
    Starr BS, Starr MS, Kilpatrick IC.
    Neuroscience; 1987 Jul 05; 22(1):179-88. PubMed ID: 2957609
    [Abstract] [Full Text] [Related]

  • 17. Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.
    Molloy AG, Waddington JL.
    Br J Pharmacol; 1988 Oct 05; 95(2):335-42. PubMed ID: 2906555
    [Abstract] [Full Text] [Related]

  • 18. Apomorphine affects cholecystokinin content via preferentially D1 or D2 dopamine receptor according to the regions of the rat brain.
    Yoshikawa T, Fukamauchi F, Shibuya H, Takahashi R.
    Neuropeptides; 1989 Oct 05; 13(2):103-5. PubMed ID: 2567971
    [Abstract] [Full Text] [Related]

  • 19. Apomorphine-induced penile erection and yawning: site of action in brain.
    Melis MR, Argiolas A, Gessa GL.
    Brain Res; 1987 Jul 07; 415(1):98-104. PubMed ID: 3497688
    [Abstract] [Full Text] [Related]

  • 20. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J.
    Eur J Pharmacol; 1985 Jul 11; 113(1):79-88. PubMed ID: 2931283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.